These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17373723)

  • 21. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
    Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.
    Nomoto M; Stahl S; Jenner P; Marsden CD
    Mov Disord; 1987; 2(1):37-45. PubMed ID: 2904119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
    Samadi P; Grégoire L; Hadj Tahar A; Di Paolo T; Rouillard C; Bédard PJ
    Neuropharmacology; 2005 Aug; 49(2):165-73. PubMed ID: 15996565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.
    Hill MP; Bezard E; McGuire SG; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
    Mov Disord; 2003 Nov; 18(11):1301-5. PubMed ID: 14639671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA; Jackson MJ; Rose S; Olanow CW; Jenner P
    Mov Disord; 2010 Feb; 25(3):377-84. PubMed ID: 20108359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
    Schneider JS; Van Velson M; Menzaghi F; Lloyd GK
    Ann Neurol; 1998 Mar; 43(3):311-7. PubMed ID: 9506547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Silverdale MA; Nicholson SL; Ravenscroft P; Crossman AR; Millan MJ; Brotchie JM
    Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Ann Neurol; 1998 Apr; 43(4):507-13. PubMed ID: 9546333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
    Jackson MJ; Al-Barghouthy G; Pearce RK; Smith L; Hagan JJ; Jenner P
    Pharmacol Biochem Behav; 2004 Nov; 79(3):391-400. PubMed ID: 15582011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Dermal application of lisuride on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset and on cases with Parkinson's disease].
    Nomoto M; Iwata S; Irifune M; Kaseda S; Osame M; Fukuda T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):81-7. PubMed ID: 9800199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model.
    Philippens IH; Joosen MJ; Ahnaou A; Andres I; Drinkenburg WP
    Behav Brain Res; 2014 Aug; 269():81-6. PubMed ID: 24769173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
    Iravani MM; Costa S; Al-Bargouthy G; Jackson MJ; Zeng BY; Kuoppamäki M; Obeso JA; Jenner P
    Eur J Neurosci; 2005 Sep; 22(6):1305-18. PubMed ID: 16190886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docosahexaenoic acid reduces levodopa-induced dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Samadi P; Grégoire L; Rouillard C; Bédard PJ; Di Paolo T; Lévesque D
    Ann Neurol; 2006 Feb; 59(2):282-8. PubMed ID: 16437566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP; Fox SH; Johnston T; Reyes G; Millan MJ; Brotchie JM
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Visanji NP; Gomez-Ramirez J; Johnston TH; Pires D; Voon V; Brotchie JM; Fox SH
    Mov Disord; 2006 Nov; 21(11):1879-91. PubMed ID: 16960862
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiparkinsonian activity of talipexole in MPTP-treated monkeys: in combination with L-dopa and as chronic treatment.
    Irifune M; Nomoto M; Fukuda T
    Eur J Pharmacol; 1994 Oct; 264(2):117-23. PubMed ID: 7851473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.